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Background. To assess the feasibility of salvage intensity-modulated radiation Therapy (IMRT) and to examine clinical outcome.
PatientsandMethods.57patientsweretreatedwithsalvageIMRTtotheprostatebedinourcenterfromJanuary,2007,toFebruary,
2010. The mean prescription dose was 68Gy in 34 fractions. Forty-four patients received concomitant androgen deprivation.
Results. Doses to organs at risk were low without altering target volume coverage. Salvage IMRT was feasible without any grade
3 or 4 acute gastrointestinal or urinary toxicity. With a median follow-up of 21 months, one grade 2 urinary and 1 grade ≥ 2
rectal late toxicities were reported. Biological relapse-free survival was 96.5% (2.3% (1/44) relapsed with androgen suppression
and 7.7% (1/13) without). Conclusion. Salvage IMRT is feasible and results in low acute and chronic side-eﬀects. Longer follow-up
is warranted to draw conclusions in terms of oncologic control.
1.Background
Any rising prostate-speciﬁc antigen(PSA) level above
0.2ng/mL in patients who have undergone prior radical
prostatectomy(RP) should be considered as a recurrence
[1, 2]. Because the site of relapse, either local or distant, is
sometimes equivocal [3, 4], absolute PSA value and PSA
kinetic parameters such as PSA velocity at recurrence [5],
interval to PSA failure [6], postoperative PSA doubling time
[7–9], and preoperative PSA velocity [10] are often used
to assess clinical outcome, although not always suitable
to predict the type of relapse. In case of local relapse,
salvage radiation therapy is able to cure selected patients
[11, 12]. Nevertheless, given the risk of morbidity associated
with the use of conventional three-dimensional conformal
radiation therapy(3D-CRT) in the postoperative setting
[13–15], most clinical trials have investigated the delivery
of low-level radiation doses ranging from 60 to 66Gy
[16–18]. In contrast, more recent studies have evaluated
the use of intensity-modulated radiation therapy (IMRT)
in conjunction or not with image-guided RT(IGRT) at
radiation doses up to 76Gy and demonstrated acute and late
toxicity proﬁles similar to those obtained with conventional
3D-CRT using standard doses [19].
In our institution, we decided to exploit the dosimetric
advantages of IMRT, primarily not to deliver escalated doses,
buttobetter spare the organs atrisk(OAR)and to reduce the
incidenceofacuteandlatetoxicities.Inthispaper,wepresent
the safety results and preliminary data regarding the short-
term biochemical control of patients treated with salvage
IMRT to the prostatic fossa.
2. Methods
2.1. Patient Selection and Follow-Up. From January, 2007,
to September 2007, the ﬁrst ten patients were treated with
postoperative IMRT to the prostate bed in our center. The
very favorable toxicity proﬁle observed in this series enabled
us to use their dosimetric plans to set our constraints after-
wards. A total of 57 consecutive patients were treated from2 ISRN Urology
January 2007 to February 2010 with IMRT to the prostate
bed for biochemical relapse after RP. Patient characteristics
are shown in Table 1. Biochemical recurrence had been
established by a rise in PSA level postoperatively. Patients
were seen every week during the course of treatment, and
acute genitourinary(GU) and gastrointestinal (GI) toxicities
were scored according to the common Toxicity Criteria for
Adverse Events scale(CTCAE 3.0). After completion of the
treatment, patients were followed every 3 to 6 months by
routine examination and PSA test. A more frequent schedule
was established in case of the occurrence of side eﬀects.
Acute toxicity was deﬁned as any side eﬀect that occurred
during treatment or within 3 months of the initiation of
radiotherapy, and the late toxicity included new or persisting
symptoms occurring 3 months or later after the start of the
treatment. Toxicity was reported as the highest toxicity in
each patient. Biochemical relapse after salvage radiotherapy
was deﬁned as a PSA value of more than nadir +0.2ng/mL or
a continued rise in the serum PSA despite IMRT.
2.2. Androgen Deprivation Therapy (ADT). The use of con-
comitant androgen deprivation was left to the physician’s
discretion, and the decision based on clinical history, patho-
logical ﬁndings, initial staging, and patient agreement. ADT
consisted of LHRH agonists, sometimes associated for the
ﬁrst month with anti-androgen to prevent the ﬂare-up eﬀect.
In total, 77% of patients underwent androgen deprivation,
but this treatment was short course (<9 months) in 84% of
them (37/44 patients). The duration of ADT ranged from 0
to 24 months.
2.3. Acquisition and Simulation. Patients were instructed
to empty their bladder before the scan according to our
in-house protocol. They underwent computed tomography
(CT)-based virtual simulation in the supine position, with
kneeandfeetsupports,butnocustomimmobilizationdevice
was used. The isocenter was set “online” in the middle of the
prostaticfossabythetreatingphysicianimmediatelyafterthe
scan, while the patient waited in the treatment position on
the scan table. The isocenter was then tattooed on the patient
skin.
2.4. Contouring and Volume Deﬁnition. Structures were
manually contoured on the CT scan according to the re-
commendations stemming from major randomized trials,
described in more detail by the EORTC Radiation Oncology
Group, the Australian and New Zealand Radiation Oncology
Genito-Urinary group, and the RTOG group [20–22]. The
clinical target volume(CTV) included the prostate bed
encompassing the vesicoureteral anastomosis, and target
volume delineation was based on surgical clips, preoperative
imaging, operative ﬁndings, and additional information
from surgical pathology. The ﬁnal length of the CTV was at
least 3cm and at most the length of the prostate gland on
the pathology report or preoperative imaging. The CTV was
extended to the seminal vesicles in case they were still visible
on the planning CT scan and included the seminal vesicle
bed in case of invasion on the RP specimen. Two planning
Table 1: Patient characteristics.
Characteristics (%)
Age, years
Range 53 – 81
Median 66
PSA before RP
Range 3.3–58.0
Median 8.1
≥5 46 81%
<5 11 19%
PSA after RP
Range 0.1–1.8
Median 0.4
≥0.2 51 89%
<0.2 6 11%
Pathological stage
pT2a 5 9%
pT2b 8 14%
pT2c 25 44%
pT3a 14 25%
pT3b 5 9%
pT4 0 0%
Surgical margins
Positive 29 51%
Negative 28 49%
Gleason score
≤6 23 40%
7 32 56%
≥82 4 %
Type of IMRT
5 coplanar ﬁelds 45 79%
VMAT (RapidArc) 12 21%
Androgen deprivation
Yes 44 77%
Short course (<9 months) 37 65%
Long course 7 12%
No 13 23%
VMAT: volumetric intensity-modulated arc therapy.
target volumes (PTVs) were deﬁned to account for daily
set-up errors and internal motion and to provide a smooth
diﬀerential dose to the CTV: PTV1 consisted of the CTV +
a 3D margin of 1cm and PTV2 consisted of the CTV + a 3D
margin of 0.5cm. The bladder was contoured in its entirety,
and the rectum as a whole organ but starting 2cm above and
below the CTV. Femoral heads were drawn from the top of
the acetabulum to the small trochanter inferiorly.
2.5. Treatment Planning and Delivery by IMRT. Prescription
doses were 68Gy in 34 fractions for 54 patients, including
the patients of the dosimetric study, and 70Gy in 35
fractions for 3 patients. Treatment plans were generatedISRN Urology 3
Table 2: Dosimetric results of the ﬁrst ten patients treated with
salvage IMRT.
Organ or volume
considered
Mean doses, Gy
(range in brackets)
D50, Gy
(range in brackets)
PTV1 67.2 (66.6–67.9)
PTV2 68.1 (67.4–68.9)
Rectum 51.4 (38.6–54.7) 54.6 (37.7–60.9)
Bladder 45.1 (39.2–62.3) 51.9 (41.2–67.4)
Femoral heads 26.1 (17.3–29.7)
D50: dose to 50% of the organ volume.
Table 3: Toxicity analysis.
Side eﬀects Grade no.(%)
I II III IV
Genitourinary
Acute 19(33) 4(7) — —
Late 9(16) 1(2) — —
Gastrointestinal
Acute 26(46) 2(4) — —
Late 4(7) — 1(2) —
using Eclipse software(Varian, PaloAlto, CA, USA) without
heterogeneity correction. Patients were treated using either
“conventional IMRT” or volumetric intensity-modulated arc
therapy(RapidArc).ForconventionalIMRT,the3D-IMRT
beam geometry consisted of ﬁve coplanar ﬁelds with gantry
angles of 60◦,9 5 ◦, 180◦, 265◦, and 300◦. An 18-MV linear
accelerator was used (21 EX, Varian, Palo Alto, CA, USA)
and IMRT was delivered using the “sliding-window” mode
of the multileaf collimator (MLC Millenium 120, Varian,
Palo Alto, CA, USA). The RapidArc technique was used
in the last patients (n = 12) with an optimization version
8.5. The treatment was delivered in a 360-degree arc with
a simultaneous variation of the gantry speed, dose rate,
and leaf position allowing IMRT dose distribution with
reduced delivery time as compared to the ﬁxed-gantry IMRT
solution. Energy of 18 MV with a maximum dose rate of 400
monitorunitsperminutewasused,andacollimatorrotation
of45◦ wasﬁxedforallpatients.TheminimumdosestoPTV1
and PTV2 were 64Gy and 68Gy, respectively. IGRT was
associatedwithIMRTusingon-boarddigitalimagingdevices
such as cone beam CT and kilovoltage X-ray, or megavoltage
X-ray imaging.
3. Results
3.1. Dose-Volume Histograms (DVHs) and Average Dose
for IMRT. The DVH generated for the ﬁrst 10 pa-
tients(Figure 1) demonstrated adequate coverage of the tar-
get volumes with 95% of volume PTV1 and PTV2 receiving
at least 95% of the prescribed doses(60.4Gy and 64.6Gy,
resp.). Detailed dosimetric data are reported in Table 2 for
this series. In order to obtain a cohort of homogeneously
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Figure 1: Average dose volume histogram for the ﬁrst 10 patients.
treated patients, we then applied the same constraints and
reached the same dose levels for all 57 patients.
3.2. Acute Toxicity. As summarized in Table 3, no patient
developed acute GU or GI toxicity greater than grade 2,
and no patient required treatment breaks because of acute
radiation-induced toxicity. Grade 2 acute toxicity was
reported in ﬁve patients (8.8%) (3 GU, 1 GI, 1 both GU
and GI). The most commonly observed GU symptoms
were pollakiuria, nycturia, and painful urination. GI toxicity
mainly included diarrhea, anal pain, and tenesmus. All
reactions could be managed with symptomatic treatments in
ambulatory setting.
3.3. Chronic Toxicity. With a median follow-up of 21
months, there was only one case of late grade 3 toxicity
(Table 3). This patient developed diarrhea up to ten stools
per day four months after completion of the treatment,
requiring 5 days of hospitalization for rehydration and
symptomatic treatment. After one month, he had recovered
with regular frequency, but persisting loose stools. A single
late grade 2 urinary adverse eﬀect was observed, which was
frequent urinary leakage. All other toxicities were grade 1.
3.4. Oncologic Control. The short-term oncologic control
wasverygoodwithonly2casesofrelapse(4%)at21months.
One patient had both biochemical and clinical relapse,
with progressive nodal disease responding to androgen
deprivation treatment. The other patient had biochemical
failure and is currently undergoing ADT. Failure rates for
patients treated with or without concomitant androgen
deprivation were 2.3% (1/44) and 7.7%(1/13), respectively.
4. Discussion
Postprostatectomy irradiation improves outcome either as
salvage or adjuvant therapy, but at the cost of increased4 ISRN Urology
GI or GU toxicity compared to no irradiation. It is not
clear however to what extent this treatment-related toxicity
impacts on quality of life as compared to observation
since the diagnosis of cancer recurrence itself, even if only
biochemical, is associated with impaired physical function
[23, 24]. It is also questionable whether adjuvant radio-
therapy, systematically given to high-risk patients with no
known recurrence, is a better cost-eﬀective option than
salvage treatment given to relapsing patients. From a clinical
point of view, the superiority of one approach over the
other will necessarily imply minimizing side eﬀects [25].
The recently updated results of the EORTC 22911 trial
presented at ESTRO 29 (Barcelona) and at ASTRO 2010
did not show any overall or metastasis-free survival beneﬁt
of adjuvant radiotherapy, possibly due to the use of early
salvage therapy in the control arm. That is in contradiction
with the results of the SWOG study [26], which had showed
a reduced risk of metastasis and an increased survival in
the adjuvant arm. To date, it cannot be stated whether
selective salvage radiotherapy is less eﬀective than adjuvant
radiotherapy, despite a clear beneﬁt on biochemical control
in favor of adjuvant radiotherapy [17, 26–28]. Some clinical
trials addressing that question are underway (RADICALS,
GETUG 17) [29–31], and hopefully, the results should help
us to better identify the patients who may avoid adjuvant
treatment and to distinguish those who would beneﬁt more
from one treatment strategy than the other. There is clear
evidence that the delivery of adjuvant radiotherapy to all
patients with high-risk features will cause more radiation-
related toxicity than salvage treatment only applied to
those who relapse [32]. Consequently, having regard to
the fact that prostatectomy for advanced stage including
T3 disease is becoming common [33–35], and until the
results from ongoing clinical trials are available, it can be
hypothesized that salvage radiotherapy will be increasingly
used, emphasizing the need for improving clinical outcome
after treatment, both in terms of disease control and side-
eﬀects [36].
Unlike the large number of studies conducted for the use
of dose-escalated radiation therapy as exclusive treatment
of prostate cancer, this strategy has not been extensively
investigated in the postoperative setting. Some randomized
controlled trials have assessed adjuvant radiotherapy using
conventionaltechniquewithprescriptiondosesrangingfrom
60 to 64Gy [16, 17]. In the salvage setting, doses up to
66Gy are usually delivered with 3D-CRT, with acceptable
but improvable toxicity rates. Nonetheless, it remains to
be proven whether further dose escalation has beneﬁcial
eﬀect on disease-free outcome. However, IMRT allows
high doses to be delivered to the target volumes while
limiting the radiation dose to the OAR [37–41]. The role
of IMRT has been widely studied for the treatment of
localized prostate cancer, and this treatment modality has
now become a standard of care for this condition [42–
46]. In contrast, there was little research in the postoper-
ative setting because of the concerns regarding cumulative
toxicity. IMRT treatment could nevertheless provide the
best therapeutic ratio, since it has been shown to decrease
radiation doses in normal tissues, including the rectum
and bladder [47, 48]. On that basis, we introduced IMRT
in our daily practice, at a dose of 68Gy, actually not for
dose escalation, but instead to minimize toxicity. Previous
studies addressing the question of postprostatectomy IMRT
had focused on diﬀerent aspects, namely, the impact of
dose escalation on clinical outcome [19, 49, 50], the eﬀect
on erectile function [51], the interest in speciﬁc radiation
modalities such as the whole pelvis irradiation [52], or
the comparison between adjuvant and salvage treatment
[53–55]. To our knowledge, our study is the ﬁrst one
addressing the dosimetric feasibility and toxicity of IMRT
without dose escalation for salvage treatment of prostate
cancer.
Furthermore, more than half of our patients had positive
margins, which is higher than other reported studies in
the salvage setting. Our results compare favorably with
previously published studies, with better results than those
using conventional 3D-CRT and similar ﬁndings to those
using IMRT. Results are promising in terms of toxicity, but
careful follow-up is required to make sure that this treatment
modality would not translate into worse oncologic outcome.
It is too early, and follow-up is too short to draw deﬁnite
conclusionsfromtheseresultswithrespecttodiseasecontrol.
Obviously, our study has several limitations. First, the
number of patient is rather low, but in return, the cohort is
homogeneous in characteristics and treatment. The follow-
up is adequate for acute toxicity and suﬃcient for late
gastro-intestinaltoxicityasitusuallymanifestswithin2years
from the treatment. However, our follow-up is too early for
a full assessment of urinary toxicity and much too short
for disease control evaluation. Moreover, toxicity reporting
using the CTCAE 3.0 scale might have underscored urgency
symptoms.
Regarding the concomitant use of androgen deprivation
with postoperative radiotherapy, data are conﬂicting, in
particular for salvage IMRT. The RTOG 85-31 trial evaluated
theeﬀectofimmediateandrogensuppressioninconjunction
with standard RT versus RT alone in a group of men eligible
for adjuvant treatment. This study did not allow deﬁnitive
conclusions, as the results were positive for freedom from
biochemical relapse, but no diﬀerences were observed for
overall survival, distant failure, and local control [56]. With
regardtosalvagetreatment,onestudyfromtheFrenchgroup
GETUG (GETUG 16) is addressing this question, and results
are pending [57]. Initial results from the RTOG 96-01 trial
presented at ASTRO meeting 2010 evaluating the beneﬁt
of adding bicalutamide to RT for salvage treatment tend to
indicate an advantage for freedom from progression. On our
side, we believe that patients undergoing salvage treatment
should be regarded as part of a very-high-risk group, taking
into consideration failure of the ﬁrst treatment, potentially
driving disease progression towards more aggressive forms.
Until ﬁnal results from ongoing trials are published, short-
course concomitant androgen deprivation (<9 months)
should be considered for those patients, and that is the
reason why the majority of our patients currently receive this
combination in this setting.ISRN Urology 5
5. Conclusions
Salvage IMRT for rising PSA level after RP is feasible and
results in very low acute and late toxicity. A longer follow-
up is warranted to evaluate the impact in terms of disease
control.
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